Dysmenorrh� bei Jugendlichen

Zusammenfassung Die primäre Dysmenorrhö tritt besonders häufig bei Jugendlichen bis zum 20. Lebensjahr auf. Sie beruht meist nicht auf pathologischen Organveränderungen. Die sekundäre Dysmenorrhö wird erst später erworben und ist bei Jugendlichen am häufigsten Symptom einer Endometriose oder anatomischer Fehlbildungen. Daher spielt die rechtzeitige Abklärung der sekundären Dysmenorrhö eine wichtige gesundheitspräventive Rolle. Die Endometriose ist bei Jugendlichen zumeist minimal oder mild ausgeprägt. Daher ist ein medikamentöser Therapieversuch mit NSAID und/oder oralen Kontrazeptiva gerechtfertigt. Ein Nichtansprechen der Beschwerden auf eine 3- bis 6-monatige medikamentöse Therapie sollte zur weiteren Abklärung veranlassen. Das Therapieziel ist die frühzeitige Erkennung von Organpathologien und die Minimierung von Dysmenorrhö und Beckenschmerzen, primär mit medikamentöser Langzeitbehandlung. Abstract Primary dysmenorrhea is especially frequent in adolescents until 20 years of age, and is usually without pelvic pathology. Secondary dysmenorrhea is acquired later, and in adolescents is most often due to endometriosis or reproductive tract anomalies. Therefore, a timely evaluation of the etiology of secondary dysmenorrhea plays an important role in preventive health care. Endometriosis in adolescents is mostly minimal or mild. For this reason, initial conservative treatment with NSAID and/or oral contraceptives is justified. If the symptoms do not respond to medical therapy within 3–6 months, further diagnostic measures are indicated. The therapeutic goal is the early recognition of pelvic pathology and maximum reduction of dysmenorrhea and pelvic pain, primarily based on long-term medical treatment. Similar content being viewed by others Literatur Andersch B, Milsom I (1982) An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol 144: 655–660 Anthuber S, Strauss A, Anthuber C, Hepp H (2003) Fehlbildungen des äußeren und inneren Genitales. Gynäkol Geburtsh Rundsch 43: 136–145 Attaran M, Gidwani GP (2003) Adolescent endometriosis. Obstet Gynecol Clin N Am 30: 379–390 Bai SW, Cho HJ, Kim JY et al. (2002) Endometriosis in an adolescent population: the severance hospital in Korean experience. Yonsei Med J 43: 48–52 Bieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H (1995) Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 9: 307–312 Brucker C (2004) Medikamentöse Therapie der Endometriose. Gynäkologe: (im Druck) Chan WY, Hill JC (1978) Determination of menstrual prostaglandin levels in non-dysmenorrheic and dysmenorrheic subjects. Prostaglandins 15: 365–375 Chan WY, Dawood MY (1980) Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. Adv Prostaglandin Thromboxane Res 8: 1443–1447 Daniels SE, Talwalker S, Torri S, Snabes MC, Recker DP, Verburg KM (2002) Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol 100: 350–358 Davis AR, Westhoff CL (2001) Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol 14: 3–8 DuRant RH, Jay MS, Shofitt T (1985) Factors influencing adolescents‘ responses to regimens of naproxen for dysmenorrhea. Am J Dis Child 139: 489–493 Ekstrom P, Juchnicka E, Laudanski T, Akerlund M (1989) Effect of an oral contraceptive in primary dysmenorrhea: changes in uterine activity and reactivity to agonists. Contraception 40: 39–47 Ekstrom P, Akerlund M, Forsling M, Kindahl H, Laudanski T, Mrugacz G (1992) Stimulation of vasopressin release in women with primary dysmenorrhea and after oral contraceptive treatment—effect on uterine contractility. Br J Obstet Gynaecol 99: 680–684 Gambone JC, Mittman GS, Munro MG, Scialli AR, Winkel CA, and the Chronic Pelvic Pain/Endometriosis Working Group (2002) Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Fertil Steril 78: 961–972 Goldstein DP, DeCholnoky C, Leventhal JM, Emans SJ (1979) New insights into the old problem of chronic pelvic pain. J Pediatr Surg 14: 675–680 Hanson FW, Izu A, Henzyl MR (1978) Naprosyn sodium in dysmenorhea: its influence in allowing work/school activities. Obstet Gyncecol: 52: 583–587 Harel Z (2002) A contemporary approach to dysmenorrhea in adolescents. Paediatr Drugs 4: 797–805 Johnson J (1988) Level of knowledge among adolscent girls regarding effective treatment for dysmenorrhea. J Adolesc Health 9: 398–402 Laufer MR, Goitein L, Bush M, Cramer DW, Emns SJ (1997) Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gyncecol 10: 199–202 Lundstrom V, Green K (1978) Endogenous levels of prostaglandin F2α and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol 130: 640–646 Marchini M, Tozzi L, Bakshi R, Pistai R, Fedele L (1995) Comparative efficacy of diclofenac dispersible 50 mg and ibuprofen 400 mg in patients with primary dysmenorrhea. A randomized, double-blind, within-patient, placebo-controlled study. Int J Clin Pharmacol Ther 33: 491–497 Mehlisch DR (1988) Ketoprofen, ibuprofen, and placebo in the treatment of primary dysmenorrhea: a double-blind crossover comparison. J Clin Pharmacol 28: 29–33 Mehlisch DR (1990) Double-blind crossover comparison of ketoprofen, naproxen, and placebo in patients with primary dysmenorrhea. Clin Ther 12: 398–409 Milsom I, Andersch B (1984) Effect of various oral contraceptive combinations on dysmenorrhea. Gynecol Obstet Invest 17: 284–292 Milsom I, Minic M, Dawood MY, Akin MD, Spann J, Niland NF, Squire RA (2003) Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea. A pooled analysis of five studies. Clin Therapeut 24: 1384–1400 Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B (1999) Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 94: 504–508 Olive DL, Pritts EA (2001) Treatment of endmetriosis. NEJM 345: 266–275 Proctor ML, Murphy PA (2003) Herbal and dietary therapies for primary and secondary dysmenorrhea. Cochrane Database of Systematic Reviews 1 Reese KA, Reddy S, Rock JA (1996) Endometriosis in an adolescent population: the Emory experience. J Pediatr Adolesc Gynecol 9: 125–128 Roy S (1983) A double-blind comparison of a propinoic acid derivative (ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhea. Obstet Gynecol 61: 628–632 Simopoulos AP (1991) Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 54: 438–463 Simpson JL, Elias S, Malinak LR, Buttram VC Jr (1980) Heritable aspects of endometriosis (I). Genetic studies. Am J Obstet Gynecol 137: 327–331 Slap GB (2003) Menstrual disorders in adolescence. Best Pract Res Clin Obstet Gynaecol 17: 75–92 Weber-Diehl F, Unger R, Lachnit U (1992) Triphasic combination of ehtinyl estradiol and gestodene: long-term clinical trial. Contraception 46: 19–27 Zahradnik HP, Breckwoldt M (1984) Contribution to the pathogenesis of dysmenorrhea. Arch Gynecol, 236: 99–108 Zahradnik HP (1984) Der Wirkungsmechanismus von Dydrogesteron bei Dysmenorrhö. Prostaglandin-Spiegel im Menstrualblut. Fortschr Med 102: 439–442 Ziaei S, Faghihzadeh S, Sohrabvand F, Lamyian M, Emamgholy T (2001) A randomised placebo-controlled trial to determine the effect of vitamin E treatment of primary dysmenorrhea. BJOG 108: 1181–1183 Interessenkonflikt: Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Brucker, C., Buck, G. Dysmenorrhö bei Jugendlichen. Gynäkologische Endokrinologie 2, 70–76 (2004). https://doi.org/10.1007/s10304-004-0058-5 Issue date: DOI: https://doi.org/10.1007/s10304-004-0058-5 Schlüsselwörter - Primäre Dysmenorrhö - Sekundäre Dysmenorrhö - Gesundheitsprävention - Abklärung - Medikamentöse Langzeitbehandlung